Nasdaq Exel News Today

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has been given a consensus rating of “Moderate Buy” by the sixteen ratings firms that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12 month price objective among […]

Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) have been given an average rating of “Moderate Buy” by the sixteen research firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average […]

Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $28.00 target price on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 27.85% from the stock’s previous close. […]

Exelixis (NASDAQ:EXEL – Free Report) had its price objective increased by TD Cowen from $25.00 to $27.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. A number of other brokerages also recently weighed in on EXEL. TheStreet raised shares of Exelixis from a […]

Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $23.46, but opened at $21.64. Exelixis shares last traded at $21.17, with a volume of 911,024 shares trading hands. The biotechnology company reported $0.12 […]

Exelixis (NASDAQ:EXEL – Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16), Briefing.com reports. The company had revenue of $425.23 million during the quarter, compared to analysts’ expectations of $461.04 million. Exelixis had a return on equity […]

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 8,620,000 shares, an increase of 26.2% from the March 31st total of 6,830,000 shares. Approximately 3.0% of the company’s shares are sold short. Based on an average […]

Meritage Portfolio Management raised its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 7.0% in the 4th quarter, Holdings Channel reports. The fund owned 422,676 shares of the biotechnology company’s stock after acquiring an additional 27,815 shares during the period. Meritage Portfolio Management’s holdings in Exelixis were worth $10,140,000 as of its most recent […]

Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year […]

Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by equities researchers at JMP Securities in a report issued on Wednesday, Benzinga reports. They presently have a $27.00 target price on the biotechnology company’s stock. JMP Securities’ target price suggests a potential upside of 14.55% from the company’s previous close. A […]